| Title |
A brief review of the management of platinum-resistant–platinum-refractory ovarian cancer
|
|---|---|
| Published in |
Medical Oncology, April 2017
|
| DOI | 10.1007/s12032-017-0960-z |
| Pubmed ID | |
| Authors |
Bryan Oronsky, Carolyn M. Ray, Alexander I. Spira, Jane B. Trepel, Corey A. Carter, Hope M. Cottrill |
| Abstract |
Ovarian cancer, which ranks fifth in cancer deaths among women, is the most lethal gynecologic malignancy. Epithelial ovarian cancer (EOC) is the most common histologic type, with the 5-year survival for all stages estimated at 45.6%. This rate increases to more than 70% in the minority of patients who are diagnosed at an early stage, but declines to 35% in the vast majority of patients diagnosed at advanced stage. Recurrent EOC is incurable. Platinum sensitivity (or lack thereof) is a major determinant of prognosis. The current standard treatment is primary surgery followed by platinum-based chemotherapy. In recurrent platinum-resistant/platinum-refractory EOC, sequential single-agent salvage chemotherapy is superior to multiagent chemotherapy. Multiagent regimens increase toxicity without clear benefit; however, no preferred sequence of single agents is recommended. The impact of targeted therapies and immunotherapies on progression-free survival and overall survival, which remains dismal, is under active investigation. Currently, clinical trials offer the best hope for the development of a new treatment paradigm in this recalcitrant disease. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 134 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 134 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 21 | 16% |
| Other | 13 | 10% |
| Researcher | 13 | 10% |
| Student > Bachelor | 12 | 9% |
| Student > Postgraduate | 10 | 7% |
| Other | 27 | 20% |
| Unknown | 38 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 32 | 24% |
| Biochemistry, Genetics and Molecular Biology | 29 | 22% |
| Chemistry | 8 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 5% |
| Agricultural and Biological Sciences | 5 | 4% |
| Other | 7 | 5% |
| Unknown | 46 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 May 2019.
All research outputs
#7,278,876
of 22,965,074 outputs
Outputs from Medical Oncology
#236
of 1,301 outputs
Outputs of similar age
#115,077
of 309,748 outputs
Outputs of similar age from Medical Oncology
#8
of 43 outputs
Altmetric has tracked 22,965,074 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 1,301 research outputs from this source. They receive a mean Attention Score of 3.1. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 309,748 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 62% of its contemporaries.
We're also able to compare this research output to 43 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.